


Galderma accelerates growth with two new launches in Japan

12 February 2026 | News

This expands Galderma's Restylane portfolio in Japan to four products



Galderma has announced the launch of Restylane Defyne and Restylane Refyne: the first Optimal Balance Technology (OBT)-based hyaluronic acid injectables ever authorised in Japan. The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.

Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma's proprietary OBT – designed to move in harmony with facial expressions while maintaining shape and lift – and are the first and only hyaluronic acid injectables clinically proven to restore youthful facial expressions.

Restylane Refyne offers a smooth, flexible gel, ideal for delicate, highly expressive areas, while Restylane Defyne provides support for areas such as the jawline and deeper facial folds. These launches mark a major milestone for Galderma and represent an important chapter in its Japan and Asia Pacific (JPAC) growth strategy, supporting the company's continuing expansion in one of the region's most dynamic aesthetics markets.

The Restylane portfolio in Japan now includes four products in total, with Refyne and Defyne joining NASHA-powered products, Restylane Classyc™ and Restylane Lyft™.

The arrival of OBT technology in Japan now aligns the market more closely with global Restylane availability, reinforcing the brand's position as the world's most scientifically studied and diverse hyaluronic acid injectables range.